(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 180.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Crinetics Pharmaceuticals's revenue in 2026 is $18,069,000.On average, 16 Wall Street analysts forecast CRNX's revenue for 2026 to be $7,374,171,827, with the lowest CRNX revenue forecast at $5,965,596,088, and the highest CRNX revenue forecast at $8,422,985,576. On average, 16 Wall Street analysts forecast CRNX's revenue for 2027 to be $19,180,628,237, with the lowest CRNX revenue forecast at $13,805,286,433, and the highest CRNX revenue forecast at $23,903,295,154.
In 2028, CRNX is forecast to generate $45,757,887,066 in revenue, with the lowest revenue forecast at $33,686,037,652 and the highest revenue forecast at $69,416,560,937.